| Literature DB >> 29949616 |
Sadia Iftikhar1, Muhammad Rehan Sarwar1,2, Anum Saqib2, Muhammad Sarfraz2,3.
Abstract
BACKGROUND AND OBJECTIVES: Adverse drug events (ADEs) are the fifth leading cause of death and thus responsible for a large number of hospital admissions in all over the globe. This study was aimed to assess the antibiotics associated preventability of ADEs and causality of adverse drug reactions (ADRs) among hospitalized patients.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29949616 PMCID: PMC6021047 DOI: 10.1371/journal.pone.0199456
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of patients.
| Characteristics | Total patients n (%) | |
|---|---|---|
| Gender | Male | 716 (57.3) |
| Female | 533 (42.7) | |
| Age | Adults (>18 years) | 865 (69.3) |
| Children (≤18 years) | 384 (30.7) | |
| Co-morbidities | Diabetes | 526 (42.1) |
| Asthma | 424 (33.9) | |
| Tuberculosis | 137 (11.0) | |
| Cystic fibrosis | 162 (13.0) | |
| Antibiotic indications | Acute respiratory tract infections | 362 (29.0) |
| Urinary tract infections | 462 (37.0) | |
| Skin and soft tissue infections | 425 (34.0) | |
| Number of antibiotics prescribed per prescription | 1 | 229 (18.3) |
| 2 | 603 (48.3) | |
| 3 | 417 (33.4) | |
*Percentages have been calculated with respect to the total sample size (n = 1249)
Antibiotics prescribed among study population.
| Antibiotics Class | ATC | Number of patients received antibiotics (n = 1,249) | Number of prescribed antibiotics (n = 2,686) |
|---|---|---|---|
| Penicillins | J01C | 194 (15.5) | 261 (9.7) |
| Macrolides | J01FA | 252 (20.2) | 311 (11.6) |
| Cephalosporins | J01D | 223 (17.9) | 292 (10.9) |
| Fluoroquinolones | J01M | 291 (23.3) | 316 (11.8) |
| Aminoglycosides | J01G | 192 (15.4) | 226 (8.4) |
| Tetracyclines | J01AA | 193 (15.5) | 221 (8.2) |
| Lincosamide | J01FF | 127 (10.2) | 209 (7.8) |
| Carbapenem | J01DH | 106 (8.5) | 234 (8.7) |
| Glycopeptide | J01XA | 91 (7.3) | 214 (7.9) |
| Oxazolidones | J01XX | 102 (8.2) | 186 (6.9) |
| Imidazole derivatives | G01AF | 113 (9.5) | 216 (8.0) |
* ATC = Anatomical Therapeutic Chemical Classification System
Effect of antibiotics on organ systems of study participants.
| Antibiotics | Total ADEs | Age groups | Cardiac | GIT | Ototoxicity | Hematology | Hepatobiliary | Renal | Neurotoxicity | Others |
|---|---|---|---|---|---|---|---|---|---|---|
| Penicillins | 62 (35.6) | Adults | 0 (0.0) | 19 (50.0) | 0 (0.0) | 2 (5.3) | 5 (13.2) | 2 (5.3) | 4 (10.5) | 6 (15.8) |
| Children | 0 (0.0) | 15 (62.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (25.0) | 3 (12.0) | ||
| Aminoglycosides | 37 (26.1) | Adults | 0 (0.0) | 2 (7.7) | 6 (23.1) | 1 (3.8) | 0 (0.0) | 9 (34.6) | 3 (11.5) | 5 (19.2) |
| Children | 0 (0.0) | 3 (27.3) | 5 (45.5) | 1 (9.1) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 0 (0.0) | ||
| Macrolides | 61 (59.8) | Adults | 6 (18.2) | 8 (24.2) | 7 (21.2) | 3 (9.1) | 4 (12.1) | 0 (0.0) | 0 (0.0) | 5 (15.2) |
| Children | 2 (7.1) | 10 (35.7) | 4 (14.3) | 0 (0.0) | 5 (17.9) | 0 (0.0) | 0 (0.0) | 7 (25.0) | ||
| Cephalosporins | 66 (33.7) | Adults | 0 (0.0) | 12 (29.3) | 0 (0.0) | 17 (41.5) | 6 (14.6) | 3 (7.3) | 2 (4.9) | 1 (2.4) |
| Children | 0 (0.0) | 1 (4.0) | 0 (0.0) | 7 (28.0) | 13 (52.0) | 3 (12.0) | 1 (4.0) | 0 (0.0) | ||
| Fluoroquinolones | 61 (67.0) | Adults | 4 (10.2) | 1 (2.6) | 9 (23.1) | 5 (12.8) | 14 (35.9) | 2 (5.1) | 3 (7.7) | 1 (2.6) |
| Children | 3 (13.6) | 7 (31.8) | 0 (0.0) | 0 (0.0) | 1 (4.6) | 4 (18.2) | 5 (22.7) | 2 (9.1) | ||
| Tetracyclines | 36 (34.9) | Adults | 0 (0.0) | 9 (39.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (26.1) | 8 (34.8) |
| Children | 0 (0.0) | 10 (76.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (23.1) | ||
| Lincosamide | 26 (26.8) | Adults | 0 (0.0) | 13 (76.5) | 0 (0.0) | 4 (23.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Children | 0 (0.0) | 6 (66.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (33.3) | ||
| Carbapenem | 34 (36.9) | Adults | 0 (0.0) | 11 (47.8) | 0 (0.0) | 8 (34.8) | 4 (17.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Children | 0 (0.0) | 5 (45.5) | 0 (0.0) | 2 (18.2) | 4 (36.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Glycopeptide | 37 (44.1) | Adults | 0 (0.0) | 4 (21.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9 (47.4) | 0 (0.0) | 6 (31.6) |
| Children | 0 (0.0) | 0 (0.0) | 8 (44.4) | 7 (38.9) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 2 (11.1) | ||
| Oxazolidones | 29 (32.2) | Adults | 0 (0.0) | 5 (23.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9 (42.9) | 7 (33.3) |
| Children | 0 (0.0) | 4 (50.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (37.5) | ||
| Imidazole derivative | 37 (47.4) | Adult | 0 (0.0) | 7 (31.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 13 (59.1) | 2 (9.1) |
| Children | 0 (0.0) | 9 (60.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (40.0) | ||
| Total | 486 (38.9) | Adults | 10 (3.3) | 91 (30.1) | 22 (7.3) | 40 (13.3) | 33 (10.9) | 25 (8.3) | 40 (13.2) | 41 (13.6) |
| Children | 5 (2.7) | 70 (38.0) | 17 (9.2) | 18 (9.8) | 23 (12.5) | 10 (5.4) | 12 (6.5) | 29 (15.8) |
*QTc >440 millisecond (ms) in males or >460 ms in females in the absence of preexisting arrhythmias, based on ≥2 electrocardiograms;
†Abdominal discomfort, nausea and vomiting associated with antibiotic administration, in the absence of an alternate explanation;
‡the ability of speech discrimination was diminished upon administration of antibiotics;
§Developed in the absence of myelosuppressive drugs and characterized as thrombocytopenia (decrease in platelet count < 150 × 103/μL), anemia (decrease in hemoglobin level <10 g/dL) and leukopenia (decrease in white blood cells level < 4500 cells/ μL);
||Characterized as increase in total bilirubin (>3 mg/dL) or alanine transaminase (>3 times patient’s baseline) or aspartate transaminase (>3 times patient’s baseline) when there was no preexisting hepatobiliary disease;
¶Characterized as high level of serum creatinine i.e. > 1.5 time baseline when there was no preexisting acute kidney injury (e.g. sepsis) or exposure to nephrotoxic drug or intravenous contrast;
**Demonstrated as antibiotic associated toxicity, peripheral neuropathy, seizures (when there was no preexisting neurologic condition) or altered mental condition;
††Other ADRs among children may include penicillins-associated hypersensitivity; macrolides-associated rashes and Stevens-Johnson syndrome; Fluoroquinolones-associated arthralgia and tendon disorders; tetracyclines-associated tooth discoloration and enamel defects; Lincosamide-associated metallic taste; Glycopeptide-associated flushing and maculopapular rash; Oxazolidones-associated red man syndrome, pruritus and oral candidiasis; imidazole-associated taste disturbance. Other ADRs among adults may include penicillins-associated hypersensitivity; aminoglycosides-associated stomatitis; macrolides-associated pancreatitis; cephalosporins-associated Stevens-Johnson syndrome, pruritus and urticaria; Fluoroquinolones-associated hypotension; Tetracyclines-associated rash, dermatitis and angioedema; Glycopeptide-associated red man syndrome and phlebitis; Oxazolidones-associated taste disturbance and polyuria; imidazole-associated taste disturbance and neuropathy.
Preventability assessment.
| Schumock and Thornton criteria | Adult (n = 302) | Child (n = 184) | Total (n = 486) |
|---|---|---|---|
| Was there a history of allergy or previous reaction to the drug? | 6 (1.9) | 5 (2.7) | 11 (2.3) |
| Was the drug involved inappropriate for the patient’s clinical condition? | 49 (16.2) | 26 (14.1) | 75 (15.4) |
| Was the dose, route, or frequency of administration inappropriate for patient’s age, weight or disease state? | 39 (12.9) | 23 (12.5) | 62 (12.8) |
| Was toxic serum drug concentration or lab monitoring test documented? | 27 (8.9) | 13 (7.1) | 40 (8.2) |
| Was there a known treatment for ADEs? | 13 (4.3) | 11 (5.9) | 24 (4.9) |
| Was therapeutic drug monitoring or other necessary lab test not performed? | 28 (9.3) | 4 (2.2) | 32 (6.6) |
| Was the drug interaction involved in ADEs? | 7 (2.3) | 5 (2.7) | 12 (2.5) |
| Was poor compliance involved in ADE? | 8 (2.7) | 9 (4.9) | 17 (3.5) |
| Were preventative measures not prescribed or administered to the patient? | 4 (1.3) | 7 (3.8) | 11(2.3) |
| If all the above criteria not fulfilled. | 121 (40.1) | 81 (44.0) | 202 (41.6) |
ADEs with respect to class of prescribed antibiotics.
| Antibiotics | ATC code | Definitely preventable ADEs | Probably preventable ADEs | Non-preventable ADEs | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Adults (n = 134) | Child (n = 78) | Total (n = 212) | Adults (n = 47) | Child (n = 25) | Total (n = 72) | Adult (n = 121) | Child (n = 81) | Total (n = 202) | ||
| Penicillins | J01C | 15 (11.2) | 10 (12.8) | 25 (11.8) | 6 (12.8) | 3 (12.0) | 9 (12.5) | 17 (14.1) | 11 (13.6) | 28 (13.9) |
| Macrolides | J01FA | 17 (12.7) | 14 (17.9) | 31 (14.6) | 3 (6.4) | 1 (4.0) | 4 (5.6) | 13 (10.7) | 13 (16.1) | 26 (12.9) |
| Cephalosporins | J01D | 20 (14.9) | 11 (14.1) | 31 (14.6) | 2 (4.3) | 4 (16.0) | 6 (8.3) | 19 (15.7) | 10 (12.4) | 29 (14.4) |
| Fluoroquinolones | J01M | 10 (7.5) | 11 (14.1) | 21 (9.9) | 11 (23.4) | 2 (8.0) | 13 (18.1) | 18 (14.9) | 9 (11.1) | 27 (13.4) |
| Aminoglycosides | J01G | 12 (8.9) | 4 (5.1) | 16 (7.5) | 4 (8.5) | 2 (8.0) | 6 (8.3) | 10 (8.3) | 5 (6.2) | 15 (7.4) |
| Tetracyclines | J01AA | 7 (5.2) | 6 (7.7) | 13 (6.1) | 7 (14.9) | 1 (4.0) | 8 (11.1) | 9 (7.4) | 6 (7.4) | 15 (7.4) |
| Lincosamide | J01FF | 4 (2.9) | 1 (1.3) | 5 (2.4) | 6 (12.8) | 4 (16.0) | 10 (13.9) | 7 (5.8) | 4 (4.9) | 11 (5.5) |
| Carbapenem | J01DH | 13 (9.7) | 5 (6.4) | 18 (8.5) | 1 (2.1) | 1 (4.0) | 2 (2.8) | 9 (7.4) | 5 (6.2) | 14 (6.9) |
| Glycopeptide | J01XA | 9 (6.7) | 8 (10.3) | 17 (8.0) | 2 (4.3) | 2 (8.0) | 4 (5.6) | 8 (6.6) | 8 (9.9) | 16 (7.9) |
| Oxazolidones | J01XX | 12 (8.9) | 4 (5.1) | 16 (7.5) | 3 (6.4) | 1 (4.0) | 4 (5.6) | 6 (4.9) | 3 (3.7) | 9 (4.5) |
| Imidazole derivatives | G01AF | 15 (11.2) | 4 (5.1) | 19 (8.9) | 2 (4.3) | 4 (16.0) | 6 (8.3) | 5 (4.1) | 7 (8.6) | 12 (5.9) |
Antibiotic associated errors in study population.
| Variables | Adult (n = 181) | Child (n = 103) | Total (n = 284) | |
|---|---|---|---|---|
| Wrong drug | 71 (39.2) | 43 (41.7) | 114 (40.1) | |
| Wrong dose | 24 (13.3) | 17 (16.5) | 41 (14.4) | |
| Wrong route | 4 (2.2) | 1 (0.9) | 5 (1.8) | |
| Wrong time | 11 (6.1) | 4 (3.9) | 15 (5.3) | |
| Deteriorated drug | 1 (0.6) | 2 (1.9) | 3 (1.1) | |
| Omission | 9 (4.9) | 6 (5.8) | 15 (5.3) | |
| Wrong dosage form | 1 (0.6) | 2 (1.9) | 3 (1.1) | |
| Non-adherence | 8 (4.4) | 9 (8.7) | 17 (5.9) | |
| Monitoring error | 52 (28.7) | 19 (18.5) | 71 (25.0) | |
| Physician ordering | 36 (19.9) | 27 (26.2) | 63 (22.2) | |
| Transcribing | 27 (14.9) | 21 (20.4) | 48 (16.9) | |
| Dispensing pharmacist | 31 (17.1) | 19 (18.5) | 50 (17.6) | |
| Nurse administering | 32 (17.7) | 14 (13.6) | 46 (16.2) | |
| Patient monitoring | 47 (25.9) | 13 (12.6) | 60 (21.1) | |
| Others | 8 (4.4) | 9 (8.7) | 17 (5.9) | |
| Lack of knowledge about the patients | 32 (17.7) | 16 (15.5) | 48 (16.9) | |
| Lack of information about antibiotics | 58 (32.0) | 33 (32.0) | 91 (32.0) | |
| Non-adherence to policies and procedures | 67 (37.0) | 42 (40.8) | 109 (38.4) | |
| Miscellaneous | 24 (13.3) | 12 (11.7) | 36 (12.7) | |
*Medication errors due to patient non-adherence;
† information about allergy, lab tests results, concomitant medications and conditions either not available or noted;
‡ indication for antibiotic use, compatibility, available dosage form, dosing guidelines and route of administration;
§ use of abbreviation in medication ordering, incomplete medication order processed, deviation from treatment protocols, delay in dispensing, use of non-standard dosing schedule, and drug preparation errors;
|| illegible handwriting of physicians, memory lapse, and unavailability of drugs.
Causality assessment with respect to antibiotics class.
| Antibiotics Class | ATC code | Patients > 18 years of age | Patients ≤ 18 years of age | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Naranjo score | Total ADRs | Naranjo score | Total ADRs | ||||||||
| Definite | Probable | Possible | Doubtful | Definite | Probable | Possible | Doubtful | ||||
| Penicillins | J01C | 1 (5.9) | 10 (58.8) | 2 (11.8) | 4 (23.5) | 0 (0.0) | 5 (45.5) | 2 (18.2) | 4 (36.4) | ||
| Macrolides | J01FA | 1 (7.7) | 3 (23.1) | 6 (46.2) | 3 (23.1) | 1 (7.7) | 2 (15.4) | 7 (53.8) | 3 (23.1) | ||
| Cephalosporins | J01D | 3 (15.8) | 7 (36.8) | 4 (21.1) | 5 (26.3) | 0 (0.0) | 1 (10.0) | 6 (60.0) | 3 (30.0) | ||
| Fluoroquinolones | J01M | 2 (11.1) | 8 (44.4) | 5 (27.8) | 3 (16.7) | 2 (22.2) | 3 (33.3) | 4 (44.4) | 0 (0.0) | ||
| Aminoglycosides | J01G | 1 (10.0) | 4 (40.0) | 3 (30.0) | 2 (20.0) | 1 (20.0) | 1 (20.0) | 2 (40.0) | 1 (20.0) | ||
| Tetracyclines | J01AA | 2 (22.2) | 0 (0.0) | 4 (44.4) | 3 (33.3) | 0 (0.0) | 3 (50.0) | 1 (16.7) | 2 (33.3) | ||
| Lincosamide | J01FF | 1 (14.3) | 3 (42.9) | 1 (14.3) | 2 (28.6) | 0 (0.0) | 2 (50.0) | 1 (25.0) | 1 (25.0) | ||
| Carbapenem | J01DH | 1 (11.1) | 3 (33.3) | 1 (11.1) | 4 (44.4) | 0 (0.0) | 3 (60.0) | 2 (40.0) | 0 (0.0) | ||
| Glycopeptide | J01XA | 0 (0.0) | 2 (25.0) | 5 (62.5) | 1 (12.5) | 2 (25.0) | 3 (37.5) | 1 (12.5) | 2 (25.0) | ||
| Oxazolidones | J01XX | 0 (0.0) | 1 (16.7) | 4 (66.7) | 1 (16.7) | 0 (0.0) | 2 (66.7) | 1 (33.3) | 0 (0.0) | ||
| Imidazole derivatives | G01AF | 0 (0.0) | 2 (40.0) | 3 (60.0) | 0 (0.0) | 1 (14.3) | 3 (42.9) | 2 (28.6) | 1 (14.3) | ||
| 12 (9.9) | 43 (35.5) | 38 (31.4) | 28 (23.1) | 7 (8.6) | 28 (34.6) | 29 (35.8) | 17 (20.9) | ||||
*Definite (≥9 score) ADRs are (1) followed a chronological sequence after the administration of drug or in which the drug had achieved a toxic concentration in the tissues or physiological fluid, and (3) could show improvement when the drug was withdrawal but reappeared on exposure;
†Probable (5–8 score) ADRs are (1) followed a chronological sequence after the administration of drug, (2) were in accordance to a recognized pattern of reactions, (3) were not confirmed by the exposure to the suspected drug but by the withdrawal of that drug, and (4) could not be described by features of the patient’s disease;
‡Possible (1–4) ADRs are (1) could be described by features of the patient’s disease, (2) followed a chronological sequence after the administration of drug, and (3) were in accordance to a recognized pattern of reactions;
§Doubtful (≤0) are factors other than a drug are associated with the reactions.
Logistic regression analysis of factors associated with ADEs.
| Characteristics | ADEs | |||||
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Gender | Male | 293 (23.5) | 423 (33.9) | 1.0 | ------ | ------ |
| Female | 193 (15.5) | 340 (27.2) | 0.047 | 0.018–0.121 | ||
| Age | Children (≤18 years) | 184 (14.7) | 200 (16.0) | 1.0 | ------ | ------ |
| Adults (>18 years) | 302 (24.2) | 563 (45.1) | 0.041 | 0.013–0.130 | ||
| Co-morbidities | Diabetes | 210 (16.8) | 316 (25.3) | 1.0 | ------ | ------ |
| Asthma | 169 (13.5) | 255 (20.4) | 0.808 | 0.598–1.093 | 0.167 | |
| Tuberculosis | 37 (3.0) | 100 (8.0) | 0.304 | 0.186–0.497 | ||
| Cystic fibrosis | 70 (5.6) | 92 (7.4) | 0.527 | 0.334–0.829 | ||
| Antibiotic indications | Urinary tract infections | 198 (15.9) | 264 (21.1) | 1.0 | ------ | ------ |
| Acute respiratory tract infections | 157 (12.6) | 205 (16.4) | 0.004 | 0.001–0.019 | ||
| Skin and soft tissue infections | 131 (10.5) | 294 (23.5)) | 0.049 | 0.018–0.133 | ||
| Number of antibiotics prescribed per prescription | 1 | 101 (8.1) | 128 (10.2) | 1.0 | ------ | ------ |
| 2 | 153 (12.2) | 450 (36.0) | 0.455 | 0.319–0.650 | ||
| 3 | 232 (18.6) | 185 (14.8) | 1.529 | 1.063–2.198 | ||
OR = Odd Ratio, CI = Confidence Interval